Literature DB >> 9260580

Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis.

R Billström1, B Johansson, T Fioretos, S Garwicz, C Malm, O Zettervall, F Mitelman.   

Abstract

Twenty-nine consecutive cases with a t(8;21)(q22;q22) in the bone marrow (BM) karyotype were retrospectively studied concerning clinical, morphological and cytogenetic data. All had been diagnosed as acute myeloid leukaemia (AML), 27 FAB subtype M2 and two M1, comprising 5% of all cytogenetically analysed AML during 18 yr. Auer rods were the most consistent t(8;21)-associated morphological finding and were demonstrated in 92% of the reviewed BM specimens, whereas BM eosinophilia was seen in only 24%. The median age was 53 yr, and 30% of the patients were > 60 yr old. Twenty-four patients had received induction chemotherapy; 22 of these (91%) entered a complete remission (CR). The median survival time in treated patients was 18 months. Leukocytosis at diagnosis (> or = 20 x 10(9)/1) was significantly (p = 0.01) associated with shorter survival time. All four children are still in first CR after 9-80 months. Seven cases (25%) developed granulocytic sarcomas, discovered either at diagnosis (n = 4) or at first relapse (n = 3). Secondary chromosome abnormalities were found in 62% of the cases, most often loss of a sex chromosome. The presence of such secondary aberrations did not correlate with any morphological or clinical characteristics, including survival. This first Scandinavian study of AML with t(8;21) corroborates the previous findings that these AMLs are characterized by distinct morphological features, a high frequency of CR and a striking tendency to develop extramedullary leukaemic manifestations. Leukocytosis at diagnosis indicates a less favourable prognosis.

Entities:  

Mesh:

Year:  1997        PMID: 9260580     DOI: 10.1111/j.1600-0609.1997.tb00958.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

2.  Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement.

Authors:  K U Park; D S Lee; H S Lee; C J Kim; H I Cho
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

Authors:  Richard F Schlenk; Marcelo C Pasquini; Waleska S Pérez; Mei-Jie Zhang; Jürgen Krauter; Joseph H Antin; Asad Bashey; Brian J Bolwell; Thomas Büchner; Jean-Yves Cahn; Mitchell S Cairo; Edward A Copelan; Corey S Cutler; Hartmut Döhner; Robert Peter Gale; Osman Ilhan; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Stephen D Nimer; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf; Mary M Horowitz; Arnold Ganser
Journal:  Biol Blood Marrow Transplant       Date:  2007-12-20       Impact factor: 5.742

4.  To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.

Authors:  Aaron T Gerds; Frederick R Appelbaum
Journal:  Clin Adv Hematol Oncol       Date:  2012-10

5.  Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells.

Authors:  Mengjie Zhao; Yu Duan; Jiangyun Wang; Yong Liu; Yao Zhao; Haihua Wang; Lei Zhang; Zhe-Sheng Chen; Zhenbo Hu; Liuya Wei
Journal:  J Oncol       Date:  2022-08-28       Impact factor: 4.501

6.  FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.

Authors:  Limin Chen; Liu-Fei Luo; Junyan Lu; Lianchun Li; Yuan-Fang Liu; Jiang Wang; Hong Liu; Heng Song; Hualiang Jiang; Sai-Juan Chen; Cheng Luo; Keqin Kathy Li
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

7.  Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Ya-Zhen Qin; Yu Wang; Hong-Hu Zhu; Robert Peter Gale; Mei-Jie Zhang; Qian Jiang; Hao Jiang; Lan-Ping Xu; Huan Chen; Xiao-Hui Zhang; Yan-Rong Liu; Yue-Yun Lai; Bin Jiang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Chin J Cancer       Date:  2016-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.